Europe is opening an earlier route for breakthrough medical devices
A new pilot lets selected high-risk devices get expert scientific input earlier. The wider programme is expected to expand in 2027.
Original image by Anecdotal
The European Medicines Agency launched a 2026 pilot that lets selected manufacturers seek expert-panel input on breakthrough status and clinical evidence for high-risk medical devices.
Why this matters
Wellness and diagnostics increasingly overlap with regulated devices. The pilot illustrates how evidence review differs from consumer-product launch language.
How the pilot works
The programme offers selected manufacturers an expert view on whether a device qualifies as breakthrough technology and advice on the clinical evidence needed under the EU Medical Device Regulation.
An initial phase runs through July 2026. A broader application window begins in September, with later phases expected to cover additional device classes.
Why consumers should care
A device can look and feel like a wellness product while making claims that bring it into a regulated category. Regulatory status depends on intended use, evidence and jurisdiction, not simply whether the product is sold in a clinic or app store.
Anecdotal uses those distinctions on device pages so “available,” “cleared,” “CE marked” and “clinically validated” are not treated as interchangeable labels.
What this is based on
Programme information from the European Medicines Agency.
Official guidance · Independent
Sources
Go straight to the source.
- 01Expert panel support for breakthrough medical devices: pilot programmeregulator
European Medicines Agency · 2026-04-28
Stay in the loop.
The diagnostics & devices stories worth opening, in one weekly email.
We never sell or share your email. Unsubscribe in one click.
Keep reading
More like this.
DeepSkin has US clearance. Here’s what that actually means.
The FDA database lists the DEP100 as an aesthetic electrical stimulator. Clearance is specific; it is not a blank cheque for every beauty claim around it.
FDA has changed the warning labels on six menopause hormone products
Specific statements about cardiovascular risk, breast cancer and probable dementia have moved out of the most prominent warning box.
The moringa outbreak is over. The recalled powder may still be in cupboards.
The investigation closed at 131 reported cases across 38 states. Because the products last for years, that is not the same as the risk disappearing overnight.